The hepatitis B vaccine is one of the most potent immunizations, usually providing decades of protection against the deadly liver virus. But in about 10% of people it doesn’t work, and in 2020, Amy Huei-Yi Lee, a systems biologist at Simon Fraser University, and her colleagues set out to determine whether they could predict who would benefit. The scientists found that data on recipients’ immune systems such as the abundance of certain proteins and the activity patterns of a few genes foretold whether they would generate defenses against the virus. “We got a sense of what factors drive the vaccine response and what [doesn’t],” Lee says.
Trending
- Oresanya highlights youth preparation for AI era at Abuja debate
- Nasarawa assembly passes health, court bills
- NERC launches net billing regulations 2026
- Association urges investment in Ebonyi rice sector
- Alake warns against attacks on NSCDC mining marshals
- For how long will threats of Northerners, Muslims’ eviction from Yoruba land continue?
- FCTA distributes 48 vein-finding devices to hospitals
- Niger Assembly approves $14.4m loan to finance Niger Foods
